Alzheimer's Mouse Models have rescued memory thanks to intranasal ligos

Alzheimer's Mouse Models have rescued memory thanks to intranasal ligos ...

Using advanced pro-resolving protein mediators intranasally arrested memory loss and brain degeneration in an experimental model of Alzheimers Disease (AD) has been discovered in a research collaboration between LSU Health New Orleans and the Karolinska Institutet in Sweden. The results are published in the Nature journal,Communications Biology, availablehere.

Neuroinflammation is a hallmark of neurodegenerative diseases, including Alzheimer''s Disease. Molecular therapies that are effective in chemotherapy and immunotherapy are also found in healthy adults. NPD1 is found in mice and is in short supply in the brains of AD patients.

Resolving inflammation is a complex process involving mediators, cell subtypes, and communication pathways. Response involves cell communication that order the activation of protective, pro-survival mechanisms, and silence pro-inflammatory signaling pathways. Specialized pro-resolving lipid mediators such as NPD1 are key signaling molecules in the process.

The report reveals solid evidence on microglial activation, pro-inflammatory signaling, chronic inflammation, and neuronal damage in Alzheimers disease. The study combines an AppNL-G-F mouse model for AD, which focuses on amyloid load, cognition, neuronal network oscillations, glial activation, receptors, and inflammation factors.

The authors argue that the noninvasive administration process, called intranasal delivery, of biologically active lipid messengers, opens the way for therapeutic treatments for AD and other neurodegenerative diseases.

AD isn''t capable of preventing or treating and has a devastating effect on patients and their families, according to Dr. Bazan, who leads the research at LSU Health. Millions of Americans currently suffer from AD, and the number of cases is expected to increase rapidly in the coming years.

Marianne Schultzberg, a senior professor of clinical neuroscience at the Karolinska Institutet (KI), has collaborated with Bazan. These include by seeing the latest findings that protect the brain in the early stages of Alzheimers disease.

According to Professor Schultzberg, this productive collaboration is revealing important aspects of the early stages of Alzheimer''s Disease, and the new advances in technology are promising avenues for innovative therapies.

Alzheimers disease is currently ranked as the seventh leading cause of death in the United States and the most common cause of dementia among older adults, according to the National Institute on Aging.

You may also like: